* 香港富豪李嘉诚旗下和黄医药0013.HK周三早盘高开3.2%，随后涨幅扩大至7.4%。
* 该公司此前公告称，沃瑞沙和泰瑞沙的联合疗法于中国获批用于治疗伴有MET扩增的一线EGFR抑制剂治疗后疾病进展的肺癌患者，此项批准亦将触发一项来自阿斯利康的1,100万美元的里程碑付款，阿斯利康在中国同时负责沃瑞沙和泰瑞沙的销售。
* 和黄医药今年迄今涨10.9%，同期恒生指数.HSI上扬20.5%。
* 恒生香港上市生物科技指数.HSHKBIO盘中一度升3.1%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 张喜良)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.